Paul Industries provides validation and commissioning in Massachusetts for biologics, cell and gene therapy, mRNA, sterile compounding and medical device plants, writing and executing the commissioning, IQ, OQ and PQ that take water, steam, clean rooms, process equipment and automation from construction to release. Massachusetts holds one of the densest concentrations of biopharma companies anywhere around Kendall Square, the Seaport and Route 128, with commercial plants in Devens, Framingham, Norwood and Worcester, and its sites range from tenant suites in shared lab buildings to campuses with their own central utilities. Paul Industries plans each qualification program around the building it sits in as well as the product it makes.

Request a quote or call 201-450-8280

Headquarters 256 Shore Drive, Kilmarnock, Virginia
Biopharma workforce 113,503 in Massachusetts in 2025 (MassBio)
Devens cell therapy plant 244,000 sq ft; commercial production approved by FDA in 2023
503B outsourcing facilities Held to CGMP in 21 CFR 210 and 211
Cambridge BEUDO Net zero by 2035 for non-residential buildings of 100,000 sq ft or more
Reviewed November 2026

Validation and commissioning in Massachusetts: what gets qualified

Validation and commissioning in Massachusetts covers the documented proof that a facility, its utilities and its process equipment are installed as designed, operate across their intended ranges, and perform consistently under real production conditions, so a plant’s quality unit can release them for GMP use. The work runs from commissioning, which is good engineering practice confirming the system works, through installation, operational and performance qualification, which the quality unit approves and which an FDA investigator may read.

In Massachusetts the scope usually includes purified water and water for injection, clean steam, compressed gases and process gases, HVAC and classified clean rooms, autoclaves and parts washers, bioreactors and media and buffer preparation, CIP and SIP, controlled temperature storage, liquid nitrogen storage for cell therapy, and the automation and data systems that run them. The national service is described on the validation and commissioning page; this page covers what the Massachusetts market, its buildings and its rules add.

Pharmaceutical companies in Massachusetts and where they make product

Pharmaceutical companies in Massachusetts cluster in three rings: research, clinical manufacturing and headquarters in Boston and Cambridge; process development and commercial biologics along Route 128; and large commercial plants along the I-495 belt and in Worcester. MassBio counted 113,503 biopharma jobs in the state in 2025 down about 3 percent from 117,108 the year before. The companies below are named as market facts about where the state manufactures and what those sites must qualify.

Pharmaceutical companies in Boston and Cambridge

Pharmaceutical companies in Boston and Cambridge occupy lab and office towers around Kendall Square, the Seaport, the Longwood Medical Area and the Fenway, where most space is leased and most manufacturing is clinical scale. Qualification in this ring is dominated by tenant fit-outs: a cell therapy or viral vector suite of a few thousand square feet, with its own air handling, purified water from a point-of-use system, single-use bioreactors and controlled-rate freezers, built inside a building whose base utilities belong to the landlord.

Biotech companies in Boston, MA and the Seaport

Vertex has been headquartered at Fan Pier in the Seaport since 2014, when it moved about 1,300 employees from Kendall Square, and the Seaport’s newer lab buildings host research and clinical production for biotech companies in Boston that lease space by the floor. Seaport buildings were often designed for labs from the start, with higher floor loads and taller floors than converted Cambridge offices, which makes room for suite air handling and utility skids.

Biotech companies in Cambridge, MA and Kendall Square

Kendall Square holds the state’s thickest concentration of biotech companies in Cambridge, MA, many in converted industrial buildings and newer towers that share central plants, risers and emergency power among dozens of tenants. Qualification there depends on clean boundaries between what the landlord maintains and what the tenant’s quality system controls, a subject covered below.

Biotech companies in Lexington, MA, Waltham and Route 128

Takeda manufactures biologics and monoclonal antibodies in Massachusetts at Lexington, Cambridge and North Reading, and the Route 128 corridor through Lexington, Waltham, Burlington and Bedford holds process development labs and mid-scale plants for many biotech companies in Lexington, MA and the surrounding towns. These sites typically run their own utilities, so water, steam and HVAC qualification is owned by one quality system from source to point of use.

Biotech companies in Devens, MA, Framingham and Norwood

Bristol Myers Squibb runs biologics production on its 89-acre Devens campus, and its 244,000 square foot cell therapy building there received FDA approval for commercial manufacturing in 2023, so the work at biotech companies in Devens, MA is commercial production rather than research. Among pharmaceutical companies in Framingham, MA, Sanofi opened a continuous, paperless biologics facility in 2019 that uses single-use equipment in place of large fixed stainless vessels. Among pharma companies in Norwood, MA, Moderna’s technology center of about 650,000 square feet is adding drug product filling, with completion targeted for the first half of 2027.

Biotech companies in Worcester, MA

Worcester’s biomanufacturing district includes WuXi Biologics’ plant at The Reactory, planned for 36,000 liters of capacity with completion targeted for 2028, alongside other biotech companies in Worcester, MA and the city’s medical research institutions. Central Massachusetts sites tend to be greenfield or large single-tenant buildings, so commissioning and qualification run on a campus model rather than a tenant suite model.

Massachusetts manufacturing settings and what each must qualify
SettingExample sites (market facts)Systems qualifiedMain qualification challenge
Tenant suites in Boston and Cambridge lab buildingsClinical cell therapy, viral vector and biologics suites in Kendall Square and the SeaportSuite HVAC and clean rooms, point-of-use water, single-use process equipment, freezersShared base-building utilities outside the tenant’s quality system
Route 128 single-tenant plantsTakeda in Lexington; process development and mid-scale plantsPurified water, clean steam, HVAC, bioreactor trains, CIP and SIPChanges inside an operating, qualified plant
Commercial cell therapyBristol Myers Squibb in DevensGrade B and A areas, isolators or biosafety cabinets, LN2 storage, chain-of-identity systemsMany identical suites qualified in waves while others run
Continuous and single-use biologicsSanofi in FraminghamSingle-use assemblies, perfusion and continuous chromatography, electronic batch recordsAutomation and data integrity carry more of the evidence
mRNA drug substance and drug productModerna in NorwoodFormulation suites, fill-finish lines, cold chain storageAseptic filling and ultra-cold storage added to an existing site
Greenfield biologics campusesWuXi Biologics in WorcesterFull utility set, large-scale bioreactors, warehousesSequencing CQV across buildings coming online at different times

Commissioning and qualification in shared Massachusetts lab buildings

Commissioning and qualification in shared Massachusetts lab buildings has to settle one question before any protocol is written: where does the landlord’s building end and the tenant’s GMP system begin. Base-building chilled water, heating hot water, emergency power, house vacuum and sometimes a building-wide RO or deionized water loop are maintained by the landlord’s engineers under a building management system the tenant’s quality unit does not control.

Paul Industries draws the qualification boundary at a physical point, usually an isolation valve, a heat exchanger, a dedicated electrical panel or a point-of-use treatment skid, and qualifies everything on the tenant side. On the landlord side, the program documents the supply conditions the tenant system needs, such as chilled water temperature or emergency power transfer time, and how the tenant will know if they change, through monitoring at the boundary and a written agreement with the building on notice of changes and shutdowns. Suites that depend on building HVAC for pressure cascades get continuous differential pressure monitoring on the GMP side, so a change upstream shows up as an alarm in the tenant’s own system.

Lease turnover adds a second Massachusetts pattern. Suites are vacated and refitted for new tenants, so qualification often starts from an existing clean room whose original records left with the previous company. In that case Paul Industries runs a gap assessment, verifies what is physically installed against current drawings, and builds the installation qualification from walk-downs, instrument calibration and new tests rather than relying on documents that no longer exist. The Massachusetts cleanrooms page covers the build side of these suites.

Cell and gene therapy plants: suites qualified in waves

Cell and gene therapy plants in Massachusetts are qualified in waves, because commercial autologous production runs many identical small suites in parallel, and new suites come online while neighboring suites are already making patient doses. A plant of the Devens scale qualifies a template suite in full, then qualifies each following suite with a reduced, risk-based protocol that verifies the installed configuration matches the template and repeats the tests that depend on the individual room.

The systems that carry the most evidence are the Grade B background rooms and the Grade A biosafety cabinets or isolators, liquid nitrogen storage and its monitoring, controlled-rate freezers, incubators, and the software that keeps chain of identity and chain of custody for each patient’s cells. Environmental monitoring performance qualification spans enough sessions to show the rooms hold their classification at rest and in operation under ISO 14644 and, for companies supplying European markets, EU GMP Annex 1 expectations. Paul Industries sequences room qualification so that construction dust, HVAC balancing and disinfectant validation in a new suite never reach the suites already in production.

Continuous and single-use biomanufacturing: what Framingham changed

Continuous and single-use biomanufacturing, of the kind Sanofi opened in Framingham in 2019, shifts qualification away from large stainless vessels and toward single-use assemblies, perfusion and continuous chromatography skids, and the automation that ties them together. A single-use bioreactor still needs installation and operational qualification of its hardware, controller, sensors and gas supply, but the bag itself is qualified through supplier documentation, extractables and leachables data and incoming inspection rather than through cleaning validation.

When a facility runs paperless, the electronic batch record, the manufacturing execution system and the data historians become part of what is qualified, and 21 CFR Part 11 controls, audit trails, user access and data backup and restore are tested in OQ alongside the process equipment. Paul Industries writes these tests into the same protocol set as the equipment they serve, so a bioreactor’s OQ includes proof that its alarms and setpoint changes are recorded in the audit trail with the right user and time.

Adding aseptic filling to a site that already makes drug substance, as Moderna’s Norwood expansion does, brings a different set of tests into an operating plant: smoke studies and airflow visualization at the filling line, isolator or restricted access barrier decontamination cycles, container closure integrity, freezer and cold room mapping for ultra-cold product, and media fills that simulate the full aseptic process. Paul Industries schedules that qualification so the new filling suite’s HVAC and utilities are proven before the line arrives, and so the tie-ins to shared water, steam and gases are qualified without disturbing the systems already released for drug substance production.

503B outsourcing facilities and the Framingham meningitis outbreak

Outsourcing facilities registered under section 503B of the Food, Drug and Cosmetic Act exist in their current form because of a Massachusetts case: the 2012 fungal meningitis outbreak traced to the New England Compounding Center in Framingham, which killed 64 people and sickened more than 700. Congress responded with the Drug Quality and Security Act of 2013, which created the 503B category, and FDA expects outsourcing facilities to meet current good manufacturing practice under 21 CFR Parts 210 and 211. Massachusetts tightened its own oversight of compounding pharmacies in 2014.

For a 503B facility or a hospital sterile compounding operation, validation and commissioning covers ISO 5 primary engineering controls and their ISO 7 and ISO 8 surrounding rooms, HVAC and pressure cascades, autoclaves and depyrogenation ovens, water systems, environmental monitoring, and the aseptic process simulations that prove the people and the process together. Paul Industries qualifies the facility and equipment to the CGMP standard FDA expects of an outsourcing facility, which is a higher bar than the pharmacy compounding chapters many of these sites started under. The sterile injectables page covers related aseptic manufacturing work.

Boston BERDO and Cambridge BEUDO beside GMP qualification

Boston’s Building Emissions Reduction and Disclosure Ordinance and Cambridge’s Building Energy Use Disclosure Ordinance push lab building owners to cut energy use, and every energy project that touches air handling, exhaust, heat recovery or central plant equipment in a GMP area has to pass through change control before it is made. BERDO 2.0 sets emissions standards for non-residential buildings over 20,000 square feet that fall every five years to net zero in 2050, and Cambridge amended BEUDO in 2023 so that its largest non-residential buildings, at 100,000 square feet and up, must hit net zero emissions in 2035.

Lab buildings, with high air change rates and once-through exhaust, are energy intensive, and reductions in air change rates, fan speed setbacks at night, conversion of steam heating to heat pumps, and heat recovery on exhaust can each move a qualified condition such as room pressure, temperature or recovery time. Paul Industries assesses each energy measure against the qualified ranges, writes the impact assessment for the quality unit, and executes the requalification tests that a change requires, so a building can meet its emissions targets without a deviation in the GMP suites it houses.

How a Massachusetts CQV program runs, stage by stage

A Massachusetts CQV program runs from user requirements and a system impact assessment through design review, factory and site acceptance tests, commissioning, IQ, OQ and PQ to a summary report that releases the system to production, following a science and risk based approach such as ASTM E2500 and the ISPE commissioning and qualification guide. The quality unit approves the requirements, the protocols and the final report, consistent with its responsibility under 21 CFR 211.22 for approving procedures and specifications.

CQV stages on a Massachusetts project and what each produces
StageWhat happensDocument produced
Requirements and impact assessmentUser requirements written; systems and components classed as direct, indirect or no impactURS, system impact assessment, critical aspects list
Design reviewDesign checked against requirements and critical aspectsDesign qualification or design review report
Factory and site acceptanceVendor skids tested at the factory and again after deliveryFAT and SAT reports, leveraged into IQ and OQ
CommissioningStartup, adjustment, balancing, functional checksCommissioning test records, punch list closure
Installation qualificationInstalled system verified against drawings, materials, calibration, documentsExecuted IQ with deviations closed
Operational qualificationFunctions, alarms, interlocks, ranges and data integrity testedExecuted OQ with deviations closed
Performance qualificationSystem run under real conditions over timeExecuted PQ, summary report, release to use

Massachusetts projects add two practical steps. Pressure vessels and boilers that are part of a qualified system, such as autoclaves, clean steam generators and bioreactor vessels, carry 522 CMR records, including the nameplate data and any National Board forms for repairs, which belong in the IQ. Process gas systems that fall inside the state’s pipefitting definition, which names hazardous gases used in biopharma manufacturing, carry their test and cleanliness records into the IQ as well; the process piping in Massachusetts page explains that classification.

Which tests prove Massachusetts biologics and cell therapy systems?

The tests that prove Massachusetts biologics and cell therapy systems depend on the system, but each must show the system holds its critical parameters across the full operating range and under production conditions, with calibrated instruments and records that meet data integrity expectations.

Qualification tests for Massachusetts biologics and cell therapy systems
SystemKey OQ testsKey PQ evidence
Purified water and WFIFlow, temperature, sanitization cycle, conductivity and TOC alarmsPhased sampling at every point of use against USP limits
Clean steamPressure control, condensate and quality testsNon-condensable gas, superheat, dryness and condensate quality over time
Classified rooms and HVACAirflow, HEPA leak, pressure cascade, recovery, alarmsParticle and microbial monitoring at rest and in operation
Biosafety cabinets and isolatorsAirflow, smoke studies, glove integrity, decontamination cycleEnvironmental monitoring during simulated and real processing
AutoclavesVacuum leak, air removal, empty chamber temperature distributionLoaded chamber heat penetration with biological indicators
Liquid nitrogen storage and controlled-rate freezersFill control, low-level alarms, temperature mapping, profile accuracyMapping under load and over the defined storage period
Single-use bioreactorsController loops, gas flow, agitation, sensor calibration, alarmsRuns at scale meeting process parameters

Water and steam qualification is detailed for the state’s plants on the high-purity water systems in Massachusetts and ultrapure water systems in Massachusetts pages, and CIP and SIP circuits on the Massachusetts CIP and SIP systems page.

What does validation and commissioning in Massachusetts cost?

The cost of validation and commissioning in Massachusetts depends on the number and complexity of systems, how many are direct impact, how much vendor testing can be leveraged, the state of existing documents in a reused suite, the number of identical suites qualified from a template, and the length of performance qualification for water and environmental monitoring. Protocol writing, execution, deviation handling and reporting each scale with those factors.

Massachusetts-specific factors include tenant suites whose base-building records have to be reconstructed, phased cell therapy suites qualified while others run, energy projects under BERDO and BEUDO that trigger requalification, and labor in the Boston market. Paul Industries prepares a budget range from the system list and the project schedule, then a firm proposal once the requirements, the design documents and the existing records have been reviewed.

Who performs validation and commissioning in Massachusetts?

Paul Industries performs validation and commissioning in Massachusetts as the contractor that writes the requirements and protocols, executes commissioning, IQ, OQ and PQ, closes deviations and hands over the summary report, and, where the owner wants it, designs, builds and installs the systems being qualified. Owners comparing validation services in Massachusetts gain from having the builder and the qualifier under one contract, because the turnover package, the commissioning tests and the qualification protocols are planned together from the start.

Massachusetts owners choose among three routes. Qualification only, where Paul Industries writes and executes the program for systems already installed or supplied by equipment vendors. Design-build, where Paul Industries designs, fabricates and installs utilities or process systems and qualifies them under the same contract. And complete installation of owner-specified equipment, with commissioning and qualification executed by Paul Industries as the final phase. Each route ends with the same deliverable: a released system and a document set the quality unit can defend in an inspection.

Paul Industries is headquartered at 256 Shore Drive in Kilmarnock, Virginia, and takes work across Massachusetts, the rest of New England and all 50 states. The same service in Paul’s home state is described on the validation and commissioning in Virginia page, and the New Jersey validation and commissioning page covers sites in the state’s pharmaceutical corridor.

Paul Industries CQV across Massachusetts

Paul Industries commissions and qualifies water and steam systems, clean rooms and HVAC, bioreactors and bioreactor installations, autoclaves, CIP and SIP, freezers and cold storage, and the automation behind them, for biotech and pharmaceutical plants from Kendall Square and the Seaport to Lexington, Devens, Framingham, Norwood and Worcester. The Massachusetts hub lists the full range of Paul work in the state. Send the system list, the project schedule and any existing qualification documents, and request a quote.

Standards referenced: 21 CFR Parts 210 and 211 · 21 CFR Part 11 · 21 CFR Part 1271 (human cells and tissues) · FD&C Act section 503B (outsourcing facilities) · ASTM E2500 · ISPE Baseline Guide Volume 5, Commissioning and Qualification · EU GMP Annex 1 and Annex 15 · ISO 14644-1 and 14644-2 · USP <1231> Water for Pharmaceutical Purposes · ASME BPE · 522 CMR (boilers and pressure vessels) · Boston BERDO 2.0 · Cambridge BEUDO

Frequently asked questions

Who provides commissioning and qualification for biotech suites in Cambridge, Kendall Square and the Seaport?

Paul Industries provides commissioning and qualification for tenant suites in Cambridge, Kendall Square, the Seaport and the Longwood area, including suite HVAC and clean rooms, point-of-use water, single-use process equipment, freezers and data systems. Each program sets a physical qualification boundary with the landlord’s base building and documents the supply conditions the suite depends on.

Can a commercial plant in Hopkinton, Marlborough or Devens get its CQV program from Paul Industries?

Yes. Paul Industries qualifies biologics, cell therapy and medical device plants in Devens, Framingham, Marlborough, Hopkinton and along the I-495 belt, covering water and steam, HVAC and clean rooms, bioreactors, autoclaves, CIP and SIP, and controlled temperature storage. Work inside operating plants follows the site’s change control and production schedule.

Who handles CQV in Worcester, Lexington and Norwood for new manufacturing buildings?

Paul Industries handles commissioning, IQ, OQ and PQ for new manufacturing buildings in Worcester, Lexington, Norwood and the surrounding towns, sequencing the program so utilities are qualified before the process equipment that depends on them, and buildings coming online at different times are tracked in one master plan.

What pharmaceutical companies are in Massachusetts?

Massachusetts hosts headquarters, research sites and plants for many global and emerging companies. Manufacturing examples include Bristol Myers Squibb’s biologics and cell therapy campus in Devens, Sanofi’s continuous biologics facility in Framingham, Moderna’s technology center in Norwood, Takeda’s biologics sites in Lexington and North Reading, and WuXi Biologics’ Worcester plant under construction, with Vertex headquartered in the Seaport. These are market facts about where the industry operates.

How many biotech companies in Massachusetts make product at commercial scale?

Commercial-scale production in Massachusetts is concentrated at a limited number of plants, while many of the state’s biotech companies run research or clinical manufacturing in leased lab space. MassBio counted 113,503 biopharma jobs statewide in 2025 and has more than 1,700 member organizations. Commercial plants cluster in Devens, Framingham, Norwood, Lexington and Worcester, where full-scale qualification programs take place.

Where are pharmaceutical companies in Boston and Cambridge located?

Pharmaceutical companies in Boston and Cambridge concentrate in Kendall Square and the surrounding Cambridge neighborhoods, the Seaport and Fan Pier, the Longwood Medical Area and the Fenway, with more along Route 128 in Lexington, Waltham and Burlington. Most occupy leased lab buildings, so their qualification work centers on tenant suites inside shared buildings.

How is a reused lab suite qualified when the previous tenant took its records?

Paul Industries runs a gap assessment, walks down the installed system against current drawings, calibrates or replaces instruments, verifies filters, materials and controls, and builds a new installation qualification from what is physically present. Operational and performance qualification then follow as for a new system, with the history of the suite recorded as context rather than relied on as evidence.

Does a change to building HVAC under BERDO or BEUDO require requalification of a GMP suite?

A change to air handling, exhaust, heat recovery or the central plant serving a GMP suite goes through the suite’s change control, and requalification is required wherever the change can move a qualified parameter such as room pressure, temperature, humidity, air changes or recovery time. Paul Industries writes the impact assessment and executes the tests the quality unit approves, before and after the energy measure.

What does a 503B outsourcing facility need to qualify?

A 503B outsourcing facility qualifies its ISO 5 primary engineering controls, ISO 7 and ISO 8 rooms, HVAC and pressure cascades, autoclaves and depyrogenation ovens, water systems, environmental monitoring program and aseptic process simulations, to the current good manufacturing practice standard in 21 CFR Parts 210 and 211. Paul Industries writes and executes those protocols with the facility’s quality unit.

How are cell therapy suites qualified when the plant adds suites in phases?

The first suite is qualified in full as a template, and each later suite is qualified with a risk-based protocol that confirms the installed configuration matches the template and repeats the room-dependent tests, such as airflow, pressure, recovery and environmental monitoring. Construction in a new suite is isolated from suites in production so that their qualified state is protected.

How are liquid nitrogen freezers qualified for a Massachusetts cell therapy plant?

Liquid nitrogen storage qualification covers fill and level control, low-level and temperature alarms, temperature mapping across the vapor phase at the storage positions, lid-open recovery, alarm notification to the people on call, and the oxygen depletion monitoring in the room. PQ maps the freezer under load over the defined period, and the supply system is checked for continuity during bulk tank deliveries.

How long does qualification take for a new Massachusetts biologics suite?

Qualification of a new biologics suite usually spans several months from protocol approval to release, set by the number of systems, the length of water performance qualification sampling, and the environmental monitoring sessions needed to show the rooms hold their classification. Leveraging vendor factory and site acceptance tests shortens execution. Paul Industries builds the schedule from the system list during planning.

Can factory acceptance tests on vendor skids count toward IQ and OQ?

Factory and site acceptance tests can be leveraged into IQ and OQ when they are executed under approved protocols, with calibrated instruments, recorded results and quality unit review, and when the system is shown to be unchanged between the test and installation. Paul Industries plans FAT and SAT content during design so the tests are written to be leveraged rather than repeated.

Are autoclave and clean steam generator records under 522 CMR part of the IQ?

Autoclaves, clean steam generators and other pressure vessels in Massachusetts fall under 522 CMR, and their nameplate data, manufacturer’s data reports and any records of welded repairs under the National Board Inspection Code belong in the installation qualification. Paul Industries collects these records with the vendor documents so the IQ shows the equipment meets the Commonwealth’s pressure equipment rules.

How much does validation and commissioning cost for a Massachusetts project?

The cost depends on the number of systems and how many are direct impact, the protocols needed, leverage of vendor testing, records missing in reused suites, the number of identical suites, and the length of performance qualification. Paul Industries prepares a budget range from the system list and schedule, then a firm proposal after reviewing the requirements, drawings and existing documents.

Can Paul Industries qualify systems that other companies built at a Massachusetts site?

Yes. Paul Industries qualifies existing systems and vendor-supplied systems, starting from the available drawings, vendor documents and turnover packages, verifying the installation in the field and filling any gaps with new tests. The same protocols and reports apply whether the system was built by Paul Industries or supplied to the site with its own documents.

What records does a Massachusetts plant receive at the end of a CQV program?

The plant receives the validation master plan or project plan, user requirements and impact assessments, design review records, commissioning records, executed IQ, OQ and PQ protocols with raw data, deviation reports and their closure, calibration records, the traceability matrix and the summary report that releases each system for use.

What should a Massachusetts site send to start a validation and commissioning proposal?

Send the system list, the project schedule, the user requirements or design basis if available, P&IDs and drawings, vendor documents for packaged equipment, any existing qualification records, and the site’s validation master plan or protocol templates. For tenant suites, include the lease responsibility split with the building. Paul Industries uses these to scope the program.

Qualifying new systems at a Massachusetts plant or lab suite?

Send the system list, the schedule, drawings and any existing qualification records. Call 201-450-8280 or request a quote.